Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks ...

A high-level overview of SpringWorks Therapeutics, Inc. (SWTX) stock. View (SWTX) real-time stock price, chart, ... SpringWorks jumps as Merck KGaA reportedly nears $3.5B buyout deal ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Shares of San Diego-based Cidara Therapeutics Inc. (NASDAQ:CDTX) were trading at $40.41, up $19.39, or 92%, on positive top-line results from its randomized, double-blind, placebo-controlled phase IIb ...

Find the latest SpringWorks Therapeutics, Inc. (SWTX) stock quote, history, news and other vital information to help you with your stock trading and investing. News. Today's news; Canada ... Merck ...